A Phase III Study of CS-8958 - A randomized double-blind comparative study of CS-8958 in patients with influenza virus infection aged 10 to 19 years -
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 04 Jun 2016 New trial record